ONYX PHARMACEUTICALS INC 4
4 · ONYX PHARMACEUTICALS INC · Filed Oct 3, 2013
Insider Transaction Report
Form 4
Lasowski Juergen
SVP, Corporate Development
Transactions
- Disposition from Tender
Common Stock
2013-10-01$125.00/sh−1,833$229,125→ 30,250 total - Disposition to Issuer
Stock Options
2013-10-01−38,548→ 0 totalExercise: $30.28From: 2011-03-31Exp: 2020-03-31→ Common Stock (38,548 underlying) - Disposition to Issuer
Stock Options
2013-10-01−925→ 0 totalExercise: $35.18From: 2012-03-31Exp: 2021-03-31→ Common Stock (925 underlying) - Disposition to Issuer
Stock Options
2013-10-01−37,575→ 0 totalExercise: $35.18From: 2012-03-31Exp: 2021-03-31→ Common Stock (37,575 underlying) - Disposition to Issuer
Stock Options
2013-10-01−2,500→ 0 totalExercise: $35.18From: 2012-03-31Exp: 2021-03-31→ Common Stock (2,500 underlying) - Disposition to Issuer
Stock Options
2013-10-01−2,653→ 0 totalExercise: $37.68From: 2013-03-30Exp: 2022-03-30→ Common Stock (2,653 underlying) - Disposition to Issuer
Stock Options
2013-10-01−43,247→ 0 totalExercise: $37.68From: 2013-03-30Exp: 2022-03-30→ Common Stock (43,247 underlying) - Disposition to Issuer
Common Stock
2013-10-01$125.00/sh−30,250$3,781,250→ 0 total - Disposition to Issuer
Stock Options
2013-10-01−37,500→ 0 totalExercise: $35.18From: 2012-03-31Exp: 2021-03-30→ Common Stock (37,500 underlying) - Disposition to Issuer
Stock Options
2013-10-01−11,212→ 0 totalExercise: $35.67From: 2009-05-19Exp: 2018-05-19→ Common Stock (11,212 underlying) - Disposition to Issuer
Stock Options
2013-10-01−72,788→ 0 totalExercise: $35.67From: 2009-05-19Exp: 2018-05-19→ Common Stock (72,788 underlying) - Disposition to Issuer
Stock Options
2013-10-01−2,625→ 0 totalExercise: $28.55From: 2010-03-31Exp: 2019-03-31→ Common Stock (2,625 underlying) - Disposition to Issuer
Stock Options
2013-10-01−3,452→ 0 totalExercise: $30.28From: 2011-03-31Exp: 2020-03-31→ Common Stock (3,452 underlying) - Disposition to Issuer
Stock Options
2013-10-01−20,100→ 0 totalExercise: $88.86From: 2014-03-28Exp: 2023-03-28→ Common Stock (20,100 underlying)
Footnotes (2)
- [F1]These restricted stock awards were cancelled at the effective time of the merger (the "Merger") pursuant to the Agreement and Plan of Merger, dated August 24, 2013, by and among Onyx Pharmaceuticals, Inc. ("Onyx"), Amgen Inc. and Arena Acquisition Company (the "Merger Agreement") in exchange for an aggregate cash payment equal to the number of shares of Onyx's common stock underlying such restricted stock awards multiplied by the per share purchase price of $125.00. Reflects the forfeiture of 8,575 performance based restricted stock units.
- [F2]Represents options to purchase Onyx's common stock that were subject to vesting over time but were cancelled in the Merger in exchange for a cash payment in the amount by which the per share purchase price of $125.00 exceeded the exercise price of the option as of the effective time of the Merger.